Phospho-PLCG2 (Tyr1217) Antibody

What is PLCγ2 and what role does phosphorylation at Tyr1217 play?

PLCγ2 (Phospholipase C gamma 2) is a phosphoinositide-specific phospholipase that generates second messengers and plays a crucial role in signal transduction. It is primarily expressed in hematopoietic cells such as B cells, mast cells, macrophages, natural killer cells, and platelets. PLCγ2 functions by hydrolyzing phosphatidylinositol 4,5-bisphosphate (PIP2) to produce inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which further propagate signaling cascades .

Phosphorylation at Tyr1217 is one of several key phosphorylation sites that regulate PLCγ2 activity. Upon stimulation of different receptors such as B-cell antigen receptor (BCR) and Fc receptors (FcRs), PLCγ2 interacts with adapter proteins and becomes phosphorylated by intracellular tyrosine kinases . This phosphorylation induces a conformational change that displaces the autoinhibitory domain, thereby activating PLCγ2's enzymatic activity . The phosphorylation status at Tyr1217 serves as an important readout of PLCγ2 activation in multiple adaptive and innate immune cell surface receptor signaling pathways .

What are the validated applications for Phospho-PLCG2 (Tyr1217) Antibody?

Phospho-PLCG2 (Tyr1217) Antibody has been validated for several research applications:

The antibody demonstrates reactivity with human and mouse samples, with endogenous sensitivity. When used for Western Blotting, the expected molecular weight is approximately 150 kDa . Unlike traditional Western Blot, newer HTRF-based assays use a plate-based format that does not require gels, electrophoresis, or transfer, providing a more streamlined approach for quantitative detection .

What is the species cross-reactivity of Phospho-PLCG2 (Tyr1217) Antibody?

The Phospho-PLCG2 (Tyr1217) Antibody demonstrates confirmed reactivity with:

While the predicted reactivity is based on 100% sequence homology at the antigen site, these species have not been experimentally confirmed in all cases . Researchers should validate antibody performance when working with species listed under predicted reactivity.

How should researchers design experiments to detect PLCγ2 phosphorylation changes?

When designing experiments to detect PLCγ2 phosphorylation changes at Tyr1217, researchers should consider several methodological approaches:

• Selection of appropriate detection method: Western blotting provides qualitative assessment of phosphorylation status, while HTRF-based assays offer quantitative detection with higher throughput capacity .

• Proper stimulation controls: Include both positive controls (stimulated cells known to induce PLCγ2 phosphorylation, such as B cells stimulated with anti-IgM) and negative controls (unstimulated cells or inhibitor-treated cells) .

• Time course considerations: PLCγ2 phosphorylation is typically transient, so researchers should establish an appropriate time course to capture peak phosphorylation events after stimulation.

• Sample preparation: Rapid lysis in the presence of phosphatase inhibitors is critical to preserve phosphorylation status, as is maintaining samples at cold temperatures during processing .

• Validation with multiple phospho-sites: Consider examining multiple PLCγ2 phosphorylation sites (Tyr753, Tyr759, Tyr1197, and Tyr1217) to gain comprehensive understanding of activation status, as different phosphorylation sites may have distinct functional implications .

It's worth noting that some researchers have chosen enhanced inositol phosphate formation as a functional readout of PLCγ2 activity rather than measuring phosphorylation directly, as it represents a more relevant functional outcome in terms of B-cell signaling .

What are the critical technical considerations when using Phospho-PLCG2 (Tyr1217) Antibody?

Several technical factors significantly influence the successful detection of phosphorylated PLCγ2:

• Appropriate sample handling: Cell lysates must be prepared with phosphatase inhibitors to prevent dephosphorylation during sample processing .

• Antibody dilution optimization: For Western Blotting, a starting dilution of 1:1000 is recommended, but researchers should optimize this based on their specific experimental conditions and detection methods .

• Blocking conditions: Proper blocking buffers are essential to minimize background signal while maximizing specific detection of phosphorylated epitopes.

• Signal normalization: When quantifying phosphorylation levels, researchers should normalize to total PLCγ2 levels by using a non-phospho-specific PLCγ2 antibody in parallel samples or after stripping and reprobing .

• Antibody validation: Confirm antibody specificity using appropriate controls such as phosphatase-treated samples or cells treated with relevant kinase inhibitors .

For Western Blotting applications specifically, the expected molecular weight is approximately 150 kDa, and researchers should be attentive to this when interpreting results to ensure they are detecting the correct protein .

How does PLCγ2 phosphorylation at Tyr1217 compare with other phosphorylation sites?

PLCγ2 contains multiple phosphorylation sites that are regulated in different contexts:

Interestingly, research indicates that in the context of ibrutinib resistance in CLL, hypermorphic PLCγ2 mutants fail to retain phosphorylation at Tyr1217 after ibrutinib treatment despite preserving the capacity to elicit downstream signaling . This suggests that phosphorylation at Tyr1217 may not be absolutely required for some PLCγ2 functions in certain contexts.

Additionally, PLCγ2 is phosphorylated at many other residues beyond the four canonical sites, including Tyr-733 and Tyr-1245, which may confound results when using phosphorylation as the sole indicator of activity . This complexity highlights the importance of considering functional readouts alongside phosphorylation status.

How does PLCγ2 phosphorylation status inform our understanding of ibrutinib resistance?

Ibrutinib resistance has emerged as a significant clinical challenge in treating B-cell malignancies such as Chronic Lymphocytic Leukemia (CLL). Research on PLCγ2 phosphorylation has revealed important insights into resistance mechanisms:

• Hypermorphic PLCγ2 mutations: Specific mutations in PLCγ2 can render it hyperactive and able to signal despite BTK inhibition by ibrutinib. Notably, these hypermorphic PLCγ2 mutants fail to retain phosphorylation at Tyr1217 after ibrutinib treatment despite preserving downstream signaling capacity .

• Noncatalytic BTK activation of PLCγ2: Research has demonstrated that various CLL-specific PLCγ2 variants (such as PLCγ2 S707Y) can be hyperresponsive to activated BTK, even in the absence of BTK's catalytic activity. This noncatalytic function of BTK may contribute to ibrutinib resistance .

• PLCγ2 variant sensitivity: The S707Y variant of PLCγ2 shows markedly increased activity when expressed with wild-type BTK, unlike wild-type PLCγ2 which remains unaffected. This differential sensitivity may explain why certain PLCγ2 variants contribute to ibrutinib resistance .

In experimental systems, catalytically-inactive BTK mutants (K430R and E41K/K430R) were unable to mediate phosphorylation of PLCγ2 at Tyr-759 or Tyr-1217, yet still activated PLC signaling in PLCγ2 variants . This suggests that phosphorylation status at these sites may not always correlate with functional activation in mutant forms of PLCγ2.

What is the relationship between PLCγ2 phosphorylation and neurodegenerative diseases?

Recent genetic association studies have highlighted a surprising connection between PLCγ2 and neurodegenerative conditions:

• Alzheimer's disease (AD) protection: A genetic variant of PLCγ2, P522R, is associated with reduced Alzheimer's disease risk (OR=0.68, p=5.38E-10) and increased longevity .

• Microglial expression: PLCγ2 is selectively expressed by microglia and functions in many immune receptor signaling pathways. In Alzheimer's disease, PLCγ2 is induced uniquely in plaque-associated microglia .

• Clinical progression impact: Among patients with mild cognitive impairment (MCI), PLCG2 P522R carriers exhibit a slower cognitive decline rate and reduced cerebrospinal fluid (CSF) total tau and phospho-tau concentrations .

• Functional alterations: Knock-in PLCG2 P522R mice show modestly increased basal phospholipase activity and macrophages with improved survival and viability, increased basal phagocytic activity, and elevated cytokine secretion .

These findings suggest that PLCγ2 phosphorylation dynamics and activity may impact microglial function in neurodegenerative contexts. While the specific role of Tyr1217 phosphorylation in these processes has not been fully elucidated, phospho-specific antibodies like Phospho-PLCG2 (Tyr1217) Antibody could be valuable tools for investigating these relationships further.

How do HTRF-based assays compare with traditional Western Blotting for PLCγ2 phosphorylation detection?

HTRF (Homogeneous Time-Resolved Fluorescence) technology offers several advantages over traditional Western Blotting for detecting PLCγ2 phosphorylation:

The HTRF cell-based assay for Phospho-PLCγ2 (Tyr1217) detection relies on an immune-complex formation involving two labeled antibodies. The first antibody specifically binds to the phosphorylated motif, while the second recognizes the protein independent of its phosphorylation state. When the protein is phosphorylated, both antibodies can bind, bringing the donor fluorophore into close proximity to the acceptor and generating a FRET signal .

This approach allows for a more streamlined workflow and potentially greater sensitivity compared to traditional Western Blotting, making it particularly suitable for screening applications or when analyzing numerous samples.

What are common challenges in detecting PLCγ2 phosphorylation at Tyr1217?

Researchers may encounter several challenges when attempting to detect PLCγ2 phosphorylation at Tyr1217:

• Transient nature of phosphorylation: Tyrosine phosphorylation events can be extremely rapid and transient, making timing critical for successful detection. Researchers must optimize stimulation time points carefully .

• Variability in stimulation conditions: The extent of PLCγ2 phosphorylation can vary significantly depending on the strength and duration of receptor stimulation. High levels of B-cell receptor activation may yield different results than lower activation levels .

• Potential confounding by other phosphorylation sites: PLCγ2 is phosphorylated at many residues beyond Tyr1217, which may complicate interpretation, especially if different sites have different kinetics or functional significance .

• Context-dependent signaling: In some cellular contexts, such as with certain PLCγ2 variants, phosphorylation status may not correlate with functional activity. For example, hypermorphic PLCγ2 mutants in ibrutinib-resistant cells fail to retain Tyr1217 phosphorylation despite maintaining signaling capacity .

• Technical issues affecting phospho-epitope detection: Sample preparation challenges include rapid dephosphorylation by endogenous phosphatases if phosphatase inhibitors are inadequate, or epitope masking due to protein-protein interactions .

For researchers encountering difficulties, comparing multiple readouts (phosphorylation status and functional outcomes like inositol phosphate formation) may provide more complete understanding of PLCγ2 activation status .

How can researchers distinguish between different PLCγ2 variants when studying phosphorylation?

Distinguishing between wild-type PLCγ2 and its variants while studying phosphorylation requires careful experimental design:

• Expression system selection: When studying specific variants, researchers can use reconstituted systems with controlled expression of wild-type versus variant PLCγ2 . This approach allows direct comparison under identical conditions.

• Multiple phosphorylation site analysis: Examining phosphorylation at multiple sites (Tyr753, Tyr759, Tyr1197, and Tyr1217) can reveal different patterns between variants. For example, some variants may show altered phosphorylation at one site but not others .

• Functional readouts alongside phosphorylation: Combining phosphorylation detection with functional assays like inositol phosphate formation provides critical context. Some variants may show discordance between phosphorylation status and functional activity .

• Dose-response relationships: Testing sensitivity to activators or inhibitors across a concentration range can reveal differences in how variants respond. PLCγ2 variants often show hypersensitivity to activators compared to wild-type .

• Genetic sequencing confirmation: For clinical samples or cell lines, genetic sequencing should confirm the presence of specific PLCγ2 variants before interpreting phosphorylation data.

Research has shown that PLCγ2 variants like S707Y exhibit markedly different phosphorylation and activation patterns compared to wild-type PLCγ2, particularly in their responses to BTK activation . These differences can be critical for understanding disease mechanisms and drug resistance.

What controls should be included when studying PLCγ2 phosphorylation in different experimental systems?

Proper controls are essential for reliable interpretation of PLCγ2 phosphorylation experiments:

For specific experimental systems studying ibrutinib resistance, additional controls should include comparisons between wild-type and variant PLCγ2 (e.g., S707Y), as well as testing with both wild-type BTK and catalytically inactive BTK variants . This approach can help delineate the complex relationships between BTK activity, PLCγ2 phosphorylation, and downstream signaling.

When using HTRF-based detection methods, technical controls should also include background fluorescence measurements and calibration standards as specified in the assay protocols .

How can phospho-specific antibodies advance understanding of PLCγ2 in neurodegeneration?

Phospho-specific antibodies like Phospho-PLCG2 (Tyr1217) Antibody can significantly advance our understanding of PLCγ2's role in neurodegeneration through several approaches:

• Microglial activation state characterization: The phosphorylation status of PLCγ2 at Tyr1217 could serve as a marker for specific microglial activation states in neurodegenerative disease contexts. Phospho-specific antibodies would allow researchers to track these changes in different disease stages .

• Protective variant mechanisms: The P522R variant of PLCγ2 is associated with reduced Alzheimer's disease risk. Phospho-specific antibodies could help determine if this protection involves altered phosphorylation dynamics at Tyr1217 or other key sites .

• Spatial and temporal profiling: Using phospho-specific antibodies in combination with advanced imaging techniques could reveal the spatial and temporal dynamics of PLCγ2 activation in relation to amyloid plaques, neurofibrillary tangles, or other pathological features .

• Therapeutic target identification: Understanding how phosphorylation at specific sites like Tyr1217 impacts PLCγ2 function in microglia could identify potential therapeutic approaches to modulate microglial responses in neurodegenerative diseases .

Future research should explore how PLCγ2 phosphorylation patterns differ between protective variants like P522R and wild-type PLCγ2 in microglial models, and how these differences relate to functional outcomes such as phagocytic activity and inflammatory responses.

What emerging technologies could enhance phospho-PLCγ2 detection and functional analysis?

Several emerging technologies hold promise for advancing PLCγ2 phosphorylation research:

• Proximity ligation assays: These techniques could enable in situ detection of phosphorylated PLCγ2 and its interactions with other signaling molecules, providing spatial context that traditional methods lack.

• Mass spectrometry-based phosphoproteomics: Quantitative phosphoproteomics could provide comprehensive mapping of all PLCγ2 phosphorylation sites simultaneously, allowing researchers to understand the relationships between different phosphorylation events .

• Single-cell phospho-flow cytometry: This approach would enable analysis of PLCγ2 phosphorylation heterogeneity within cell populations, particularly valuable for studying primary patient samples or heterogeneous tissue like microglia in brain samples.

• CRISPR-based phosphorylation site mutants: Creating precise mutations at specific phosphorylation sites using CRISPR genome editing would allow definitive determination of individual phosphorylation site functions.

• Biosensors for real-time phosphorylation monitoring: Development of FRET-based biosensors specific for PLCγ2 phosphorylation could enable real-time monitoring of phosphorylation dynamics in living cells.

These technological advances could be particularly valuable for understanding the complex relationship between PLCγ2 phosphorylation and function in contexts such as ibrutinib resistance in CLL or microglial responses in neurodegenerative diseases .

How might PLCγ2 phosphorylation research inform development of new therapeutic strategies?

Research on PLCγ2 phosphorylation has significant potential to inform novel therapeutic approaches:

• Targeting BTK-PLCγ2 interaction in ibrutinib resistance: Understanding the noncatalytic mechanisms by which BTK can activate certain PLCγ2 variants could lead to new therapeutic strategies that target protein-protein interactions rather than just kinase activity .

• Alternative kinase inhibitors: Research showing that SYK and LYN can combat molecular resistance in CLL models suggests that targeting these kinases may provide alternative strategies to overcome ibrutinib resistance related to PLCγ2 variants .

• Microglial modulation for neurodegeneration: The protective effects of the PLCγ2 P522R variant in Alzheimer's disease suggest that pharmacological approaches mimicking this variant's effects on microglial function could have therapeutic potential .

• Combination therapy strategies: Understanding the phosphorylation-dependent and -independent activation mechanisms of PLCγ2 could inform rational combination therapy approaches that target multiple nodes in the signaling pathway.

• Phosphorylation-specific targeting: Development of therapeutic antibodies or small molecules that specifically recognize and modulate phosphorylated forms of PLCγ2 could provide highly specific intervention strategies.

Future therapeutic development will benefit from detailed understanding of how different phosphorylation patterns correlate with functional outcomes in normal physiology and disease states, with phospho-specific antibodies like Phospho-PLCG2 (Tyr1217) Antibody playing a crucial role in this research .